This protocol is judged by an institutional review board, an independent group that assessments any scientific trials involving human beings. If a analyze involves a Schedule I drug, when the board approves the protocol as ethical, the researchers have to make an application for an investigational new drug (IND) variety with the FDA.Prospects desc